PHVS · Insider Trading
Pharvaris N.V. Ordinary Shares
Every open-market purchase and sale reported by PHVS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Peng Lu | President | F | −226 | −$7.03K |
| 2026-09-25 | Viviane Monges | Director | MIXED | — | −$299.17K |
| 2026-09-24 | Johannes Gerardus Christiaan Petrus Schikan | Director | MIXED | — | −$12.95K |
| 2026-09-24 | Peng Lu | President | M | +45,308 | +$117.35K |
| 2026-09-23 | David W. Nassif | CFO / CLO | MIXED | −6,500 | −$218.80K |
| 2026-09-21 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | −200,000 | −$7.00M |
| 2026-09-21 | Robert Glassman | Director | MIXED | — | −$295.91K |
| 2026-09-21 | Elisabeth Bjork | Director | MIXED | — | −$1.17M |
| 2026-09-21 | Berndt Modig | Chief Executive Officer | M | −300,000 | −$10.50M |
| 2026-09-21 | Anne Lesage | Chief Early Development | Sell | −20,000 | −$765.47K |
| 2026-09-21 | Peng Lu | President | MIXED | — | −$3.24M |
| 2026-09-17 | Stefan Andreas Abele | Chief Technical Ops Officer | MIXED | −1,400 | −$1.03M |
| 2026-09-17 | Robert Glassman | Director | MIXED | — | −$138.36K |
| 2026-09-16 | Wim Souverijns | Chief Commercial Officer | MIXED | −6,090 | −$674.98K |
| 2026-09-15 | Berndt Modig | Chief Executive Officer | Sell | −2,291 | −$90.28K |
| 2026-09-15 | Peng Lu | President | MIXED | −226 | −$571.63K |
| 2026-09-14 | Anne Lesage | Chief Early Development | MIXED | — | −$907.58K |
| 2026-09-11 | Robert Glassman | Director | MIXED | — | −$140.40K |
| 2026-09-09 | Peng Lu | President | MIXED | — | −$571.28K |
| 2026-08-18 | Berndt Modig | Chief Executive Officer | Sell | −2,292 | −$79.69K |
| 2026-08-13 | Peng Lu | President | F | −226 | −$7.82K |
| 2026-07-15 | Berndt Modig | Chief Executive Officer | Sell | −2,292 | −$80.15K |
| 2026-07-14 | Peng Lu | Chief Medical Officer | F | −226 | −$7.93K |
| 2026-07-01 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | −37,600 | −$1.33M |
| 2026-07-01 | Anne Lesage | Chief Early Development | MIXED | −37,700 | −$2.43M |
| 2026-06-29 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | −2,400 | −$84.25K |
| 2026-06-29 | Anne Lesage | Chief Early Development | MIXED | −2,300 | −$150.69K |
| 2026-06-29 | Peng Lu | Chief Medical Officer | MIXED | — | −$941.91K |
| 2026-06-23 | Peng Lu | Chief Medical Officer | MIXED | — | −$9.42K |
| 2026-06-17 | Berndt Modig | Chief Executive Officer | Sell | −2,291 | −$71.17K |
| 2026-06-16 | Peng Lu | Chief Medical Officer | F | −117 | −$3.77K |
| 2026-06-15 | Peng Lu | Chief Medical Officer | F | −109 | −$3.43K |
| 2026-06-08 | Anna Nijdam | Principal Accounting Officer | Sell | −2,670 | −$82.43K |
| 2026-05-26 | David W. Nassif | CFO / CLO | Sell | −10,000 | −$303.08K |
| 2026-05-26 | Viviane Monges | Director | Sell | −9,667 | −$292.85K |
| 2026-05-26 | Anna Nijdam | Principal Accounting Officer | MIXED | — | −$78.46K |
| 2026-05-22 | Elisabeth Bjork | Director | MIXED | — | −$212.67K |
| 2026-05-22 | Berndt Modig | Chief Executive Officer | — | — | — |
| 2026-05-20 | Berndt Modig | Chief Executive Officer | Sell | −2,292 | −$66.98K |
| 2026-05-19 | Wim Souverijns | Chief Commercial Officer | Sell | −10,000 | −$299.16K |
| 2026-05-19 | Stefan Andreas Abele | Chief Technical Ops Officer | Sell | −8,748 | −$260.86K |
| 2026-05-19 | Robert Glassman | Director | MIXED | −4,667 | −$179.27K |
| 2026-05-13 | Peng Lu | Chief Medical Officer | F | −226 | −$6.78K |
| 2026-05-05 | Peng Lu | Chief Medical Officer | MIXED | — | −$390.73K |
| 2026-05-01 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | −32,900 | −$996.54K |
| 2026-05-01 | Anne Lesage | Chief Early Development | MIXED | −22,900 | −$1.30M |
| 2026-05-01 | Peng Lu | Chief Medical Officer | MIXED | — | −$517.34K |
| 2026-04-24 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | −7,100 | −$213.38K |
| 2026-04-24 | Peng Lu | Chief Medical Officer | MIXED | — | −$195.01K |
| 2026-04-24 | Anne Lesage | Chief Early Development | MIXED | −7,100 | −$383.82K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Berndt Modig | Chief Executive Officer | 778,334 | $26.72M |
| Anne Lesage | Chief Early Development | 130,419 | $4.48M |
| Johannes Gerardus Christiaan Petrus Schikan | Director | 115,167 | $3.95M |
| David W. Nassif | CFO / CLO | 113,800 | $3.91M |
| Peng Lu | President | 110,152 | $3.78M |
| Stefan Andreas Abele | Chief Technical Ops Officer | 85,468 | $2.93M |
| Anna Nijdam | Principal Accounting Officer | 46,275 | $1.59M |
| Wim Souverijns | Chief Commercial Officer | 39,021 | $1.34M |
| Elisabeth Bjork | Director | 15,167 | $520.68K |
| Robert Glassman | Director | 10,500 | $360.46K |
| Viviane Monges | Director | 5,500 | $188.81K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PHVS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.